Skip to main
EQ

Equillium Inc (EQ) Stock Forecast & Price Target

Equillium Inc (EQ) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Equillium is positioned for success with their innovative approach to treating severe autoimmune and inflammatory disorders through their lead asset, EQ504. However, challenges lie ahead in terms of fundraising and securing regulatory approval. While the company has other assets and potential expansion opportunities, further human data is needed to fully assess the drug's potential toxicities. Overall, Equillium holds strong potential for growth and success in the biotechnology industry, but investors should be aware of the potential risks and uncertainties involved in their drug development process. Their financials and patent portfolio provide a strong foundation for the company's future success.

Bears say

Equillium is at a critical stage in its development with the potential launch of its new drug EQ504, however, the company faces significant risks such as potential clinical failure, safety concerns, and competition from bigger pharmaceutical players. The company also faces stiff competition from other drugs being developed for the treatment of ulcerative colitis. While the company has enough funding until 2029, its success will ultimately depend on the results of its Phase 1 trials and its ability to successfully launch and market its drug in a highly competitive market. Additionally, any delay in its clinical development process could lead to decreased investor confidence and potential financial struggles for the company.

Equillium Inc (EQ) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Equillium Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Equillium Inc (EQ) Forecast

Analysts have given Equillium Inc (EQ) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Equillium Inc (EQ) has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Equillium Inc (EQ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.